Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1

Conditions

Advanced Nonhematologic Malignancies 1Advanced Non-hematologic Malignancies 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × TAK 733 × Clear all
NCT01613261 2013-11-01

Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic Malignancies

Millennium Pharmaceuticals, Inc.

Phase 1 Withdrawn

Advanced Nonhematologic Malignancies

NCT00948467 2013-07-02

Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies

Millennium Pharmaceuticals, Inc.

Phase 1 Completed
51 enrolled
Dermatologic

Advanced Non-hematologic Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡